Cellyan Biotechnology
HKPD
6 hedge funds and large institutions have $93.5K invested in Cellyan Biotechnology in 2025 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 1 closing their positions.
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
68% more capital invested
Capital invested by funds: $55.8K → $93.5K (+$37.7K)
50% more funds holding
Funds holding: 4 → 6 (+2)
0.2% more ownership
Funds ownership: 0.47% → 0.67% (+0.2%)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$25.5K |
| 2 |
VNA
Valley National Advisers
Bethlehem,
Pennsylvania
|
+$16.1K |
| 3 |
TSS
Two Sigma Securities
New York
|
+$12.8K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$386 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
-$16.2K |
| 2 |
CS
Clear Street
New York
|
-$4.57K |
| 3 |
Jane Street
New York
|
-$4.53K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
UBS Group
Zurich,
Switzerland
| $26.7K | +$25.5K | +20,603 | +7,575% |
|
|
2
Jane Street
New York
| $21.8K | -$4.53K | -3,664 | -18% |
|
|
VNA
3
Valley National Advisers
Bethlehem,
Pennsylvania
| $16K | +$16.1K | +13,000 | New |
|
|
CS
4
Clear Street
New York
| $15.4K | -$4.57K | -3,700 | -24% |
|
|
TSS
5
Two Sigma Securities
New York
| $13.2K | +$12.8K | +10,329 | New |
|
|
TRCT
6
Tower Research Capital (TRC)
New York
| $399 | +$386 | +312 | New |
|
|
WAM
7
Warberg Asset Management
Winnetka,
Illinois
| – | -$16.2K | -15,000 | Closed |
|
HKPD Hedge Fund Activity: Q2 2025 in Review
6 of the 7,598 institutional investors tracked by Wall St. Rank reported a position in Cellyan Biotechnology (HKPD) for Q2 2025, worth a combined $93.5K — up 68% from $55.8K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new HKPD positions and 1 closed out — a net gain of 2 holders — while 1 added to existing stakes and 2 trimmed.
The largest buyer was UBS Group, adding an estimated $25.5K. The largest seller was Warberg Asset Management, exiting entirely with an estimated $16.2K sold.
- 6 institutional investors held Cellyan Biotechnology (HKPD) as of Q2 2025, up from 4 in Q1 2025.
- Funds reported $93.5K of Cellyan Biotechnology stock for Q2 2025, up 68% quarter-over-quarter.
- 3 funds opened new Cellyan Biotechnology positions in Q2 2025 and 1 closed out, a net change of +2 holders.
- The largest Cellyan Biotechnology buyer in Q2 2025 was UBS Group, an estimated $25.5K added.
- The largest Cellyan Biotechnology seller in Q2 2025 was Warberg Asset Management, an estimated $16.2K sold.
Based on aggregated 13F filings for Q2 2025.